Filing Details

Accession Number:
0001103021-20-000081
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-12 18:48:32
Reporting Period:
2020-05-08
Accepted Time:
2020-05-12 18:48:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1301715 A Mark Sirgo C/o Biodelivery Sciences Intl, Inc.,
4131 Parklake Avenue, Suite 225
Raleigh NC 27612
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-05-08 100,000 $5.07 1,264,595 No 4 S Direct
Common Stock Acquisiton 2020-05-11 22,500 $0.00 1,287,095 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2020-05-11 22,500 $0.00 22,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-05-11 2020-05-11 No 4 M Direct
Footnotes
  1. The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
  2. On May 8, 2020, the Reporting Person sold an aggregate of 100,000 shares of the Issuer's Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.29 per share and the lowest sale price was $5.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
  3. The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended.